My Treatment Approach: NSCLC Testing and Management of Complex Cases - Episode 1

My Treatment Approach: NSCLC Testing and Management of Complex Cases

,

Two expert oncologists discuss the critical role of comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They emphasize that molecular testing is an essential part of the initial diagnosis, not an optional add-on, as it identifies specific mutations and fusions that dictate the most effective first-line treatment.

Now Viewing
EP. 1: My Treatment Approach: NSCLC Testing and Management of Complex Cases
EP. 2: Tissue is Critical: Best Practices for NSCLC Biomarker Testing
EP. 3: NSCLC Case Study 1: Staging & Diagnostic Workup for a Lung Nodule
EP. 4: NSCLC Case Study 1: Essential Molecular Testing for New Lung Cancer Diagnosis
EP. 5: NSCLC Case Study 1: PD-L1 30% and No Mutations
EP. 6: Managing Recurrent NSCLC After Immunotherapy & Surgery
EP. 7: The Role of DNA & RNA in Comprehensive Genomic Profiling
EP. 8: NSCLC Case Study 2: A Never-Smoker with Neuroendocrine Markers

Mark Socinski, MD details his institution's approach, which involves two primary testing panels. A rapid 50-gene panel provides results for common, actionable mutations in about seven business days. A more extensive 500-gene panel takes slightly longer but helps identify patients eligible for clinical trials based on rarer genetic alterations. The discussion also notes that other tests, like PD-L1, are often sent to external labs, and plasma-based testing is used. The overarching goal is to use this comprehensive diagnostic information to guide personalized treatment decisions and improve patient management.